NMD Pharma A/S

9 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jun 2036

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Feb 20 to 22, 2027 · next Feb 20

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 10,934,244	Compounds for use in treating neuromuscular disorders In force Term ends Jun 15, 2036 · From the USPTO record	In force	Term ends Jun 15, 2036	From the USPTO record
US 10,385,028	Compounds for the treatment of neuromuscular disorders In force Term ends Dec 14, 2037 · From the USPTO record	In force	Term ends Dec 14, 2037	From the USPTO record
US 11,147,788	Compounds for the treatment of neuromuscular disorders In force Ends no later than Dec 14, 2037 · From the USPTO record	In force	Ends no later than Dec 14, 2037	From the USPTO record
US 11,591,284	Compounds for the treatment of neuromuscular disorders In force Term ends Dec 14, 2037 · From the USPTO record	In force	Term ends Dec 14, 2037	From the USPTO record
US 12,440,477	Compounds for the treatment of neuromuscular disorders In force Term ends Dec 14, 2037 · From the USPTO record	In force	Term ends Dec 14, 2037	From the USPTO record
US 11,730,714	Compounds for the treatment of neuromuscular disorders In force Term ends Dec 29, 2037 · From the USPTO record	In force	Term ends Dec 29, 2037	From the USPTO record
US 12,168,643	Compounds for the treatment of neuromuscular disorders In force Term ends Mar 5, 2041 · From the USPTO record	In force	Term ends Mar 5, 2041	From the USPTO record
US 12,221,425	Process for the Preparation of CLC-1 Chloride Channel Inhibitors In force Term ends Jan 11, 2042 · High confidence	In force	Term ends Jan 11, 2042	High confidence
US 12,415,771	Compounds for the Treatment of Neuromuscular Disorders In force Term ends Oct 21, 2042 · High confidence	In force	Term ends Oct 21, 2042	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 no status recorded

List them